Preventing and treating secondary bacterial infections with antiviral agents
Identifieur interne : 001005 ( Ncbi/Checkpoint ); précédent : 001004; suivant : 001006Preventing and treating secondary bacterial infections with antiviral agents
Auteurs : Jonathan A. MccullersSource :
- Antiviral therapy [ 1359-6535 ] ; 2011.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (usage thérapeutique), Enfant d'âge préscolaire, Essais contrôlés randomisés comme sujet, Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Infections bactériennes (), Infections bactériennes (traitement médicamenteux), Modèles animaux de maladie humaine, Oséltamivir (usage thérapeutique), Pneumopathie bactérienne (), Pneumopathie bactérienne (traitement médicamenteux), Résultat thérapeutique, Souris, Sous-type H1N1 du virus de la grippe A.
- MESH :
- traitement médicamenteux : Grippe humaine, Infections bactériennes, Pneumopathie bactérienne.
- usage thérapeutique : Antiviraux, Oséltamivir.
- virologie : Grippe humaine.
- Animaux, Enfant d'âge préscolaire, Essais contrôlés randomisés comme sujet, Grippe humaine, Humains, Infections bactériennes, Modèles animaux de maladie humaine, Pneumopathie bactérienne, Résultat thérapeutique, Souris, Sous-type H1N1 du virus de la grippe A.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Bacterial Infections (complications), Bacterial Infections (drug therapy), Bacterial Infections (prevention & control), Child, Preschool, Disease Models, Animal, Humans, Influenza A Virus, H1N1 Subtype, Influenza, Human (complications), Influenza, Human (drug therapy), Influenza, Human (virology), Mice, Oseltamivir (therapeutic use), Pneumonia, Bacterial (complications), Pneumonia, Bacterial (drug therapy), Pneumonia, Bacterial (prevention & control), Randomized Controlled Trials as Topic, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiviral Agents, Oseltamivir.
- complications : Bacterial Infections, Influenza, Human, Pneumonia, Bacterial.
- drug therapy : Bacterial Infections, Influenza, Human, Pneumonia, Bacterial.
- prevention & control : Bacterial Infections, Pneumonia, Bacterial.
- virology : Influenza, Human.
- Animals, Child, Preschool, Disease Models, Animal, Humans, Influenza A Virus, H1N1 Subtype, Mice, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of influenza. The association of secondary bacterial pathogens with fatal pneumonia during the recent H1N1 influenza pandemic highlights the need for new development in this area. Basic and clinical research into viral-bacterial interactions over the last decade has revealed several mechanisms that underlie this synergism. By applying these insights to antiviral drug development, the potential exists to improve outcomes by means other than direct inhibition of the virus.
Url:
DOI: 10.3851/IMP1730
PubMed: 21447860
PubMed Central: 4907367
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000898
- to stream Pmc, to step Curation: 000898
- to stream Pmc, to step Checkpoint: 000829
- to stream PubMed, to step Corpus: 001053
- to stream PubMed, to step Curation: 001053
- to stream PubMed, to step Checkpoint: 000E72
- to stream Ncbi, to step Merge: 001005
- to stream Ncbi, to step Curation: 001005
Links to Exploration step
PMC:4907367Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preventing and treating secondary bacterial infections with antiviral agents</title><author><name sortKey="Mccullers, Jonathan A" sort="Mccullers, Jonathan A" uniqKey="Mccullers J" first="Jonathan A." last="Mccullers">Jonathan A. Mccullers</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21447860</idno><idno type="pmc">4907367</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907367</idno><idno type="RBID">PMC:4907367</idno><idno type="doi">10.3851/IMP1730</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000898</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000898</idno><idno type="wicri:Area/Pmc/Curation">000898</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000898</idno><idno type="wicri:Area/Pmc/Checkpoint">000829</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000829</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:21447860</idno><idno type="wicri:Area/PubMed/Corpus">001053</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001053</idno><idno type="wicri:Area/PubMed/Curation">001053</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001053</idno><idno type="wicri:Area/PubMed/Checkpoint">000E72</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E72</idno><idno type="wicri:Area/Ncbi/Merge">001005</idno><idno type="wicri:Area/Ncbi/Curation">001005</idno><idno type="wicri:Area/Ncbi/Checkpoint">001005</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Preventing and treating secondary bacterial infections with antiviral agents</title><author><name sortKey="Mccullers, Jonathan A" sort="Mccullers, Jonathan A" uniqKey="Mccullers J" first="Jonathan A." last="Mccullers">Jonathan A. Mccullers</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><idno type="eISSN">2040-2058</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Bacterial Infections (complications)</term><term>Bacterial Infections (drug therapy)</term><term>Bacterial Infections (prevention & control)</term><term>Child, Preschool</term><term>Disease Models, Animal</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human (complications)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (virology)</term><term>Mice</term><term>Oseltamivir (therapeutic use)</term><term>Pneumonia, Bacterial (complications)</term><term>Pneumonia, Bacterial (drug therapy)</term><term>Pneumonia, Bacterial (prevention & control)</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Enfant d'âge préscolaire</term><term>Essais contrôlés randomisés comme sujet</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Infections bactériennes ()</term><term>Infections bactériennes (traitement médicamenteux)</term><term>Modèles animaux de maladie humaine</term><term>Oséltamivir (usage thérapeutique)</term><term>Pneumopathie bactérienne ()</term><term>Pneumopathie bactérienne (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Souris</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Bacterial Infections</term><term>Influenza, Human</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bacterial Infections</term><term>Influenza, Human</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Bacterial Infections</term><term>Pneumonia, Bacterial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infections bactériennes</term><term>Pneumopathie bactérienne</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Child, Preschool</term><term>Disease Models, Animal</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Mice</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Enfant d'âge préscolaire</term><term>Essais contrôlés randomisés comme sujet</term><term>Grippe humaine</term><term>Humains</term><term>Infections bactériennes</term><term>Modèles animaux de maladie humaine</term><term>Pneumopathie bactérienne</term><term>Résultat thérapeutique</term><term>Souris</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p id="P1">Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of influenza. The association of secondary bacterial pathogens with fatal pneumonia during the recent H1N1 influenza pandemic highlights the need for new development in this area. Basic and clinical research into viral-bacterial interactions over the last decade has revealed several mechanisms that underlie this synergism. By applying these insights to antiviral drug development, the potential exists to improve outcomes by means other than direct inhibition of the virus.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Mccullers, Jonathan A" sort="Mccullers, Jonathan A" uniqKey="Mccullers J" first="Jonathan A." last="Mccullers">Jonathan A. Mccullers</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001005 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001005 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= PMC:4907367
|texte= Preventing and treating secondary bacterial infections with antiviral agents
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:21447860" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |